



For Immediate Release

VENTRIPOINT ANNOUNCES APPOINTMENT OF NEW DIRECTOR

SEATTLE, WASHINGTON, October 28, 2010 – VentriPoint Diagnostics Ltd. (TSXV: VPT) is pleased to announce the appointment of Brad Harlow as a new member to its Board of Directors.

“It is with greatest pleasure I welcome Brad to VentriPoint,” stated Treuman Katz, Chair of the Board. “Brad’s expertise in ultrasound and previous success in building and partnering such businesses will assist us in our objective to build shareholder value as we increase patient care and lower the cost of cardiac imaging in hospitals worldwide.”

Brad Harlow strengthens VentriPoint’s Board with his extensive technology background in health care, including software, ultrasound and cardiology. Mr. Harlow is the Managing Partner of B. Harlow & Associates, LLC which advises med-tech companies for financing, Mergers & Acquisitions and buyouts. His group has led over \$200 million in financing, asset/division sales and new technology investments over the last 10 years. Mr. Harlow also serves as the Chairman of Commerce Bridge Company LLC, a private business-to-business lending company and as the CEO of PhysioSonics, a neuromonitoring start up using ultrasound technology for monitoring blood flow in the brain.

Previously, he served as Senior Vice President of publicly listed Data Critical, which was acquired by GE Medical in 2002. Data Critical’s systems enhanced the quality, cost, efficiency, safety and outcome of healthcare. Brad began his career at ATL Ultrasound and Spacelabs Medical. Brad received a BS in Accounting from Oregon State University, an MBA from Seattle University and has taught executive programs in Finance at the USC School of Business.

The addition of Brad Harlow to the Board is a key component of the CEO’s strategic plan to strengthen VentriPoint for growth...” add directors with a strategic focus”.

About VentriPoint Diagnostics Ltd. VentriPoint creates diagnostic tools to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application with additional applications in process to enable monitoring of all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a \$10 Billion market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration.

For further information, please contact:

VentriPoint Diagnostics Ltd.
Ed Garth, Chief Financial Officer
Telephone: (206) 283-0221, ext. 402
Facsimile: (206) 283-2309



Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.